IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Pharmacological Management Of Type 2 Diabetes: A Comprehensive Review Of Metformin's Mechanisms And Enduring First-Line Efficacy

By: Vedant Shailendra Borkar, Mayur Dharmraj Santape, Rakshit Rakesh Kanojiya, Mohit Rajesh Nandanwar, Gayatri M Chinchulkar

Index Terms: Type 2 Diabetes Mellitus (T2DM), Metformin, Antihyperglycemic Agents, Mechanism of Action (or Metformin's Mechanisms), Hepatic Glucose Production (HGP), AMP-Activated Protein Kinase (AMPK), Biguanide

Abstract: For more than 60 years, Metformin, a synthetic biguanide chemically derived from Galega officinalis, has been the first and most frequently chosen one of the first-line antihyperglycemic agents in the treatment of Type 2 Diabetes Mellitus (T2DM) patients. Its multifactorial mechanism of action in conjunction with a good safety profile and some cardio-protective effects make long-term use essentially the main reason for its continuous effectiveness. The major part of antidiabetic effect is due to the inhibition of Hepatic Glucose Production (HGP). Metformin after it is delivered to the liver cell via Organic Cation Transporter 1 (OCT1), only mildly inhibits mitochondrial respiratory chain Complex I. Due to the inhibition of oxidative phosphorylation, the cell experiences energetic stress; hence the AMP/ATP ratio increases and the irradiated AMP-Activated Protein Kinase (AMPK) is one. The activated AMPK then down-regulates the genes for gluconeogenesis (for example, PEPCK, G6Pase), glucose production being lowered accordingly. Metformin also alters the liver in a way that does not depend on AMPK. One of those ways involves glucagon ceasing stimulation of the cAMP pathway and at the same time inhibiting mitochondrial glycerol-3-phosphate dehydrogenase (mGPD). On the top of that, metformin doesn't depend entirely on the liver (extrahepatic/gut-mediated) mechanisms. Most of metformin's effect occurs in the intestine hence muscle glucose uptake is a result of increased gut glucose uptake by metformin. In addition, incretin hormone (GLP-1 and PYY) secretion which, among other things, is the main cause of the weight-neutral/weight-loss effect in metformin treated individuals, is also increased. Metformin is usually indicated to be the cause of an HbA1c reduction effect of 1.0% to 1.5%. The landmark UK Prospective Diabetes Study (UKPDS) provided the main proof of metformin's supremacy by demonstrating a substantial decrease of the first-time myocardial infarction and all-cause mortality in overweight individuals - a cardiovascular protection effect, which was prolonged and deepened for 20 years ("legacy effect"). In general, the medication is safe but some dose-related gastrointestinal symptoms have been reported as the most common side effects. The most important med, though seldom, risk is Metformin-Associated Lactic Acidosis (MALA) which mainly occurs in patients with

renal impairment (eGFR <30 mL/min/1.73 m2). Also, the long-term exposure requires the monitoring of Vitamin B12 deficiency. In addition to that, Metformin has a few more potential effects on the positive side like anticancer capability via IMPK-mTOR pathway suppression, a good effect on PCOS and probably a gero protective agent (the focus of the TAME Trial). New drug classes (SGLT2i, GLP-1RA) with solid CVOT data are slowly but surely putting metformin in second place for patients with established cardiovascular disease as first-line treatment, however, it remains the most logical, evidence-based, cost-effective, and indispensable foundation for pharmacological intervention of T2DM worldwide.

Introduction: Metformin, The Enduring Cornerstone of T2DM Therapy

Metformin is a synthetic biguanide, orally effective and insulin sensitizing anti-diabetic drug, which for most patients is the first line anti-hyperglycemic for the treatment of type 2 diabetes mellitus (T2DM). Metformin was first synthesized in 1922 and its development was based on knowledge from folk medicine that the active, but toxic, constituent from *Galega officinalis* (French lilac) that could treat 'sweet urine' was the guanidine, galegine. Metformin was introduced to treat T2DM in France in 1958 and now after over 60 years is used on a daily basis by over 150 million people. For the majority of people metformin is not only an inexpensive drug as it is off patent but also a safe drug with the most prominent side effects being gastrointestinal-related that occur in about 20-30% of patients and can include abdominal pain, bloating, diarrhea, nausea and vomiting. The GI-side effects are dose-dependent and do not usually limit its use; however, in approximately 5% of subjects these side effects can result in the need to switch to an alternative drug. [1]

For over 60 years, there has been one drug that has been universally regarded as the first-line pharmacotherapy for T2DM: Metformin. Metformin is derived from the biguanide class based on the herb, Galega officinalis. Its sustained position in clinical practice is remarkable, especially in the current landscape of increasing new drug classes (e.g. GLP-1 RAs, SGLT2 inhibitors) that are now available. The reference for Metformin practice was largely founded on the UK Prospective Diabetes Study (UKPDS), which showed not only a significant reduction in HbA1c but also a significant reduction in myocardial infarction and total mortality in overweight participants, something that was not demonstrated with any other drug at that time. [2]

Even though Metformin has been around for a long time, its unique molecular mechanisms remain an active area of scientific research that goes beyond the historical concept of AMP-activated protein kinase (AMPK) activation and inhibition of hepatic glucose production. More recently, investigation of the gut-micro biome axis and AMPK-independent pathways has demonstrated contributions to this multifaceted drug's effect.

This definitive review article aims to outline Metformin's role as an efficacious therapeutic agent in Type 2 Diabetes Mellitus (T2DM) by presenting a comprehensive examination focused upon three pillars:

1) a thorough breakdown of the mechanisms of cellular action, encompassing both hepatic and extrahepatic targets;

2) a critical evaluation of its cellular biological action on a historical context in first-line efficacy and its pivotal long-term cardiovascular outcomes in guiding clinical providers' global community use; and

3) an examination of its years-long pleiotropic effects, including in oncology (mTOR signaling) and its application in polycystic ovary syndrome (PCOS) and age-associated diseases. This review aims to help synthesize decades of clinical research, cellular biology, and evidence to reinforce development while comprehensively considering Metformin's across-the-board role as the efficacious foundation agent in the pharmacological management of T2DM. [3]

2. Pharmacokinetics and Target Organ Concentration of Metformin

The unique efficacy of metformin is inextricably linked to its distinct pharmacokinetic properties, particularly its dependence on specialized membrane transporters that determine its absorption, distribution, and critical concentration in its primary target organ: the liver.

2.1 Physicochemical Properties and Oral Bioavailability

Metformin hydrochloride is a tiny, strong base (pKa≈12.4) with a high degree of hydrophilicity. At the blood and gut physiological pH of ≈7.4, metformin is nearly entirely in its cationic (positively charged) form.

- **Oral Bioavailability**: Metformin has a poor and insufficient oral bioavailability, often between 40 and 60 percent. This is mostly explained by the drug's poor lipid solubility (caused by its cationic composition) and its reliance on transport proteins to get through the intestinal membrane.
- **Site of Absorption:** The duodenum and jejunum, which are parts of the small intestine, are the primary locations where the absorption is delayed.
- The peak plasma concentrations (Cmax) for immediate-release (IR) are usually achieved in 1-3 hours, whereas for extended-release (XR) it is 4-6 hours. [4]

Table 1: Absorption of metformin throughout the human body

Compartment	**Action**	**Transporters/Result**
Oral Dose ➡ **Gut Lumen**	Ingestion	Dose enters the gut.
Gut Lumen ➡ **Systemic Circulation**	**Absorption**	Only **40-60%** is absorbed.
Gut Lumen (Unabsorbed Drug)	**GI Effects**	⬆ High concentration causes dose-dependent side effects (diarrhea) and beneficial secondary actions (**GLP-1** release).

2.2 Distribution and the Critical Role of Organic Cation Transporters (OCTs)

Metformin is not plasma protein-bound to a significant extent, and therefore it is able to flow freely. Its distribution is under tight control by a group of transporters, mainly OCTs and Multidrug and Toxin Extrusion (MATE) proteins.

- **Hepatic Uptake (OCT1):** Among the various transporters, Organic Cation Transporter 1 (OCT1), situated on the basolateral membrane of hepatocytes, is the most vital one. OCT1 through the process of active transport metformin is brought to the liver cells. This process is the reason for metformin concentrations in the liver to be 3 to 5 times higher than those in the plasma or portal vein. It is this high local concentration that is important, as the liver is the main place of metformin action, where it stops gluconeogenesis. The genetic polymorphisms in the gene coding for OCT1 (SLC22A1) that cause changes in metformin effectiveness and are a point of pharmacogenomics research.

Table 2: Distribution and action of metformin

Compartment	Action	Transporters/Result
Systemic Circulation ➡ **Liver**	**Distribution & Action**	Metformin is actively transported into the liver cells.
Liver	**Uptake**	Primarily mediated by the **OCT1 Transporter**.
Liver (Result)	**Primary Site of Action**	Decreases **Hepatic Glucose Production (HGP)**.

- **Gastrointestinal Concentration:** In particular, the unabsorbed portion of metformin can be as high as 60 percent and is thus anted in the intestinal lumen, which results in very high concentrations in the intestinal wall. This is an essential element in the support of the "Two Sites" hypothesis, which suggests that a major part of the drug's therapeutic effect passes through the gut (for instance, increased GLP−1 secretion, changed glucose metabolism).

2.3 Metabolism and Renal Elimination

Metformin is exceptional among type 2 diabetes drugs as it is not metabolized by the liver (no Cytochrome P450 enzymes involvement).

• **Elimination**: Metformin is excreted unchanged nearly only through the kidneys. This removal is mostly through active tubular secretion, which is facilitated by OCT2 and MATE transporters.

➢ **Renal Secretion**: OCT2 that is located on the baso lateral membrane of renal tubular cells is the metformin co-transporter from the blood into the cell.

Table 3: Metabolism and Excretion of metformin

Compartment	Action	Transporters/Result
Systemic Circulation → Kidney	**Excretion**	Metformin is **actively cleared**, excreted unchanged in the urine.
Kidney	**Clearance**	Involves **OCT2** (uptake into renal cells) and **MATE1/2** (secretion into urine).
Kidney (Risk)	**MALA Risk**	Clearance dependence creates increased risk of **Lactic Acidosis (MALA)** if kidney function is severely impaired (**eGFR < 30 mL/min**).

- **Excretion:** MATE1 and MATE2-K, which are located on the apical (luminal) membrane, thus actively pump metformin into the tubular fluid for final excretion by urine.

• **Half-Life:** The plasma elimination half-life is normally short, about 4-6 hours.

• **Clinical Importance:** Since metformin clearance is linearly related to creatinine clearance, removal from the body is very slow in patients with renal failure. This decreased elimination causes metformin levels to rise in the body, which leads to a substantially increased risk of the most severe side effect: Metformin-Associated Lactic Acidosis (MALA). This pharmacokinetic information is the reason why dose adjustments are always required and the drug should be progressively stopped in patients with low estimated glomerular filtration rate (eGFR). [5]

3. The Multifaceted Molecular Mechanism of Metformin Action

Metformin is remarkably effective in type 2 diabetes, and this is due to its complicated, multi-faceted mechanism that involves various organs. Its main function is to reduce blood sugar levels, however, on a molecular level, its actions are both AMPK-dependent and AMKP-independent, and thus, isolation of the affected organ becomes difficult. Nevertheless, most of the effects are attributed to the liver, with the intestines and peripheral tissues playing a part.

3.1. Primary Mechanism: Inhibition of Hepatic Glucose Production (HGP)

The principal glucose-lowering action of metformin is to decrease the production of glucose in the liver (HGP), which is a condition that has gone awry in type 2 diabetes (T2DM) where the liver has become resistant to insulin. The process by which a series of events starting in the hepatocyte mitochondria leads to this outcome is one such cascade.



Fig 1: Metformin's Primary Mechanism

A. Mitochondrial Inhibition and Energy Stress

1. Complex I Inhibition: Metformin, which is transported into liver cells by the OCT1 transporter, inhibits to some extend the mitochondrial respiratory chain Complex I (NADH dehydrogenase). This weak inhibition changes the electron transport chain.

2. AMP/ATP Ratio Shift: The damage results to a drop in ATP production. As a result, the energy state of the cell is under tension, which leads to a corresponding rise in the AMP/ATP ratio.

B. Activation of AMPK (The Canonical Pathway)

The increased AMP/ATP ratio serves as a signal to open the gate for AMP-Activated Protein Kinase (AMPK), a primary metabolic sensor. The AMPK energized works to bring back the energy balance in the cell by:

1.Repressing Gluconeogenic Genes: The AMPK initiation interferes with the production and the function of the enzymes which by nature are involved in the synthesis of glucose, for example, Phosphoenolpyruvate Carboxykinase (PEPCK) and Glucose-6-Phosphatase (G6Pase).

2.Inhibiting Glucagon Signaling: AMPK is capable of antagonizing the action of glucagon, which is a cofactor that facilitates HGP, thus, it can indirectly nullify the effects of glucagon.

3.2. AMPK-Independent Mechanisms

Research indicates that certain impacts still happen even if the levels of AMPK activation are not very high:

• **Glucagon-cAMP Suppression:** Metformin can locally block the enzyme adenylyl cyclase, which is responsible for the formation of cyclic AMP (cAMP). As glucagon signaling depends on cAMP, less glucose output from the liver will be caused, which is a glucagon signal-independent way of AMPK cascade.

• **Redox-Dependent Mechanism:** Metformin is believed to inhibit mitochondrial Glycerol-3-Phosphate Dehydrogenase (mGPD) at clinically relevant concentrations. This inhibition changes the cellular redox potential, which inhibits gluconeogenesis non-competitively with substrates such as glycerol and lactate. [6]

3.3. Extrahepatic and Gut-Mediated Actions

Although liver is the main target, the actions in the gut and muscle compensate for a big part of the total glucose control:

1. Enhanced Peripheral Glucose Uptake: Metformin strengthens the action of insulin in the skeletal muscle and the fat tissue. The AMPK that is activated in the muscle encourages the movement of the glucose transporter GLUT4 to the cell membrane where the glucose is taken from the blood and the amount of glucose that enters the cell is increased.

2. Gut Glucose Utilization: Metformin is present in the intestinal wall in very high concentrations. It facilitates the non-oxidative metabolism of glucose by enterocytes (glucose-to-lactate conversion), thus, glucose from the blood is used effectively before it reaches the liver.

3. Incretin Hormone Release: Metformin causes the release of Glucagon-Like Peptide-1 (GLP−1) and Peptide YY (PYY) from intestinal L-cells. This process precedes β-cell recruitment, decreases energy intake, and gives rise to weight-neutral or weight-loss effects.

4. Gut Microbiota Modulation: Metformin shifts the gut microbiota composition and metabolic activities, leading to an increase of the good bacteria and short-chain fatty acids (SCFAs), which might be having systemic effects on metabolism and inflammation. [7]

4. Clinical Efficacy and The Definitive Role as First-Line Therapy of Metformin

Whether metformin is still the first drug to be given to patients suffering from type 2 diabetes (T2DM) is not only a matter of history, but also the result of clinical evidence unmatched by other drugs showing high effectiveness in the control of glycemia, a good safety profile, and, what is most important, the prevention of macrovascular complications over a long period.

4.1. Glycemic Efficacy and Durability

Metformin is classified as a highly effective oral glucose-lowering agent. Its efficacy stems from directly addressing a core defect in T2DM: excessive Hepatic Glucose Production (HGP).

- **Potency:** As mono therapy, metformin typically reduces glycosylated hemoglobin (HbA1c) levels by **1.0% to 1.5%**. This reduction is comparable to or greater than that achieved by other monotherapy classes, such as sulfonylureas (SUs) or dipeptidyl peptidase-4 (DPP−4) inhibitors, particularly when initiated early in the disease course.
- **Insulin Sensitization and β-Cell Preservation:** By improving insulin sensitivity in the liver and muscle, metformin reduces the demand on the struggling pancreatic β-cells. Evidence suggests it may contribute to **greater durability of glycemic control** compared to SUs, delaying the time until secondary therapies (like insulin) are required.
- **Risk Profile:** A hallmark of metformin's safety is its **virtually non-existent risk of hypoglycemia** when used alone. Since it acts by reducing HGP and increasing peripheral glucose uptake rather than stimulating insulin secretion, it does not drive blood glucose below the physiological threshold.
- **Weight Management:** Unlike insulin and SUs, which often cause weight gain, metformin is generally **weight-neutral or associated with modest weight loss** (typically 1-3 kg). This is a significant advantage, as most patients with T2DM are overweight or obese. The weight benefit is partially linked to its GLP−1 effects and its known anorectic effects.

4.2. The Landmark UK Prospective Diabetes Study (UKPDS)

The long-term clinical foundation for metformin rests squarely on the findings of the UK Prospective Diabetes Study (UKPDS), the most influential trial in T2DM history.

The UKPDS34 Results

The UKPDS was a randomized controlled trial that compared intensive glucose control using various therapies (metformin, SUs, insulin) against conventional diet control in newly diagnosed T2DM patients.

- **Macrovascular Superiority:** In the specifically randomized subgroup of **overweight/obese patients** receiving metformin monotherapy (n=342), the drug demonstrated a superior reduction in long-term cardiovascular outcomes compared to the conventional arm (primarily diet):
    - **32% reduction in any diabetes-related endpoint** (p=0.0023).
    - **39% reduction in myocardial infarction (MI)** (p=0.010).
    - **36% reduction in all-cause mortality** (p=0.011).

Crucially, the intensive glucose control achieved by SUs or insulin in the general UKPDS cohort did not yield a similar significant reduction in macrovascular events, suggesting that metformin's benefits extended **beyond mere glucose lowering** to include true cardiovascular protection.

The "Legacy Effect" (Metabolic Memory)

The UKPDS was followed by a 10-year post-trial observation period. During this time, the difference in HbA1c between the intensive and conventional groups largely disappeared. Nevertheless, the mortality and cardiovascular risk reduction benefits of the original metformin group **persisted and strengthened** over the entire 20-year observation period:

- **33% reduction in MI.**
- **27% reduction in all-cause mortality.**

This phenomenon, known as the **"legacy effect"** or metabolic memory, implies that early, aggressive treatment with metformin fundamentally alters the trajectory of the disease, providing benefits that endure long after glycemic separation is lost. This is the strongest evidence supporting the rationale for starting metformin immediately upon diagnosis.

4.3. Metformin's Role in Modern Guidelines and Combination Therapy

Metformin's proven safety, efficacy, and cost-effectiveness position it as the mandated foundation for all T2DM treatment algorithms published by major bodies (ADA, EASD, AACE).

The Standard of Care

The current consensus recommendation dictates:

1. **Initial Therapy:** Lifestyle modification and **Metformin** initiation at the time of T2DM diagnosis for most patients.
2. **Maintenance:** Metformin should be **continued** as long as it is tolerated and not contraindicated, even when other agents are added.

Metformin in Combination Therapy

Metformin is a nearly perfect partner for all other glucose-lowering drug classes because it targets a different core defect (HGP/Insulin Resistance) than those that primarily target insulin secretion (SUs, GLP−1RAs) or renal function (SGLT2 inhibitors).

Metformin Combination	Rationale for Use
+ SUs	Provides high HbA1creduction by combining insulin sensitization with increased insulin secretion (Note: SU risk of hypoglycemia increases).
+ DPP−4 Inhibitors	Combines HGP reduction with increased endogenous in cretin effect (good synergy, low risk of hypoglycemia).
+ SGLT2 Inhibitors	Combines HGP reduction with renal glucose excretion (excellent cardio renal protection, often preferred in high-risk patients).
+ GLP−1 RAs	Combines HGP reduction with profound appetite suppression and β-cell stimulation (high efficacy, weight loss, strong CV benefit).

The Cardio renal Challenge to First-Line Status

The emergence of SGLT2 inhibitors and GLP−1RAs with proven, dedicated cardiovascular outcomes trial (CVOT) data for reducing Major Adverse Cardiovascular Events (MACE), hospitalization for heart failure, and progression of CKD has introduced the primary modern controversy:

- **Metformin is still first-line for patients without ASCVD or CKD.**
- **However, for patients with established ASCVD, heart failure, or CKD, SGLT2i or GLP−1RA is recommended as the preferred initial addition or, increasingly in severe cases, the preferred first-line agent, irrespective of HbA1c.**

5. Safety Profile, Contraindications, and Risk Mitigation of Metformin

Metformin is generally considered safe and well-tolerated, a primary reason for its first-line status. However, its use requires careful attention to potential side effects, specific contraindications, and appropriate risk mitigation strategies.

5.1. Gastrointestinal Adverse Effects (Common)

Gastrointestinal (GI) symptoms are the most frequent side effects, typically affecting up to 30% of patients, and are the most common cause of discontinuation.

- **Symptoms:** Include diarrhea, nausea, vomiting, flatulence, and abdominal discomfort. These effects are thought to be related to the high concentration of unabsorbed metformin in the intestinal lumen and its effect on intestinal motility and glucose metabolism.
- **Mitigation Strategies:**
    - **Slow Titration:** Initiating the dose low (e.g., 500 mg once daily) and increasing gradually over several weeks significantly improves tolerance.
    - **Dosing with Meals:** Taking metformin with or immediately after food reduces peak plasma and intestinal concentrations.
    - **Extended-Release (XR) Formulation:** The XR formulation often causes fewer GI side effects compared to the immediate-release (IR) version and may be used for patients who cannot tolerate IR metformin.

5.2. Metformin-Associated Lactic Acidosis (MALA) (Rare but Serious)

Lactic acidosis is the most serious, though extremely **rare**, adverse effect of metformin. The risk of this life-threatening condition is confined almost exclusively to patients with significant predisposing conditions that impair metformin clearance or predispose to tissue hypoxia.

- **Mechanism:** While complex, the theoretical risk arises from metformin's mild inhibition of mitochondrial Complex I, which can shift peripheral and hepatic metabolism toward anaerobic glycolysis, increasing lactate production. MALA only occurs when the drug accumulates to toxic levels or when underlying conditions severely compromise tissue oxygenation.
- **Risk Mitigation and Contraindications:**
    - **Renal Impairment:** Because metformin is excreted un metabolized by the kidneys, **impaired renal function** is the chief risk factor for drug accumulation and MALA.

        - Metformin is **contraindicated** if the estimated glomerular filtration rate (eGFR) is **<30 mL/min/1.73 m2**.
        - Dose reduction and close monitoring are mandatory for an eGFR between 30 and 45 mL/min/1.73 m2.
    - **Acute/Severe Illness:** Metformin should be **temporarily discontinued** (held) in any setting that causes acute CKD, hypoxia, or circulatory collapse (e.g., sepsis, acute heart failure, severe liver failure, hypoxemia) due to the heightened risk of lactic acidosis.
    - **Procedures:** Metformin must be held before any radiologic procedure involving **iodinated contrast media** and before most surgical procedures, to prevent potential accumulation from temporary changes in renal function or systemic stress. [8]

5.3. Vitamin B12 Deficiency (Long-Term Risk)

Long-term metformin use, particularly at higher doses, has been associated with a **reduced absorption of Vitamin B12** (cobalamin).

- **Mechanism:** Metformin is thought to interfere with the calcium-dependent binding of the B12-intrinsic factor complex in the terminal ileum.
- **Clinical Relevance:** Chronic deficiency can lead to macrocytic anemia and, more concerningly, **peripheral neuropathy**.
- **Risk Mitigation:** Current guidelines recommend **periodic monitoring** of B12 levels (and/or screening for anemia/neuropathy) in patients taking metformin long-term, especially those with pre-existing anemia or neuropathy. Supplementation may be necessary. [9]

6. Pleiotropic Effects and Emerging Therapeutic Applications of Metformin

Metformin's clinical utility extends far beyond its primary role in glycemic control, encompassing a range of **pleiotropic effects** that influence cardiovascular health, cell proliferation, and potentially longevity. These actions are largely attributed to the systemic metabolic changes and the activation of the AMPK pathway in various tissues.

6.1. Cardiovascular Protection: Beyond Glucose Lowering

Metformin's macrovascular benefits, first suggested by the UKPDS legacy effect, are distinct from those achieved by pure glucose-lowering. These protective effects are mediated by non-glycemic mechanisms:

- **Improved Endothelial Function:** Metformin enhances nitric oxide (NO) bioavailability, which is critical for vascular health. This improves vasodilation and reduces arterial stiffness.
- **Anti-Inflammatory Effects:** Metformin exhibits anti-inflammatory properties by inhibiting key inflammatory pathways, such as NF-κB signaling, reducing the chronic, low-grade inflammation characteristic of insulin resistance and atherosclerosis.
- **Lipid Profile:** It modestly improves the lipid profile, typically by lowering serum triglycerides and LDL-cholesterol levels.

- **Atherosclerosis:** Metformin may directly inhibit the proliferation of vascular smooth muscle cells and reduce oxidative stress, contributing to plaque stabilization and reducing the progression of



atherosclerosis.

Fig 3: Persistent Cardiovascular Benefit of Metformin

6.2. The Anti-Cancer Hypothesis and mTOR Signaling

Metformin has garnered significant attention for its potential anti-cancer properties, based on both epidemiological and mechanistic evidence.

- **Epidemiological Findings:** Observational studies and meta-analyses suggest that metformin use in diabetic patients is associated with a **reduced incidence and improved prognosis** for several common cancers, notably colorectal, breast, pancreatic, and liver cancers.
- **Molecular Rationale:** The anti-cancer effect is primarily linked to its central metabolic regulator:
  - **AMPK and mTOR Inhibition:** The activation of AMPK by metformin leads to the inhibition of the **mammalian Target of Rapamycin (mTOR)** pathway. mTOR is a critical regulator of cell growth, proliferation, and survival, and is frequently hyperactive in cancer. By suppressing mTOR, metformin may inhibit tumor cell growth.
  - **Reduced Hyperinsulinemia:** Metformin lowers circulating insulin levels, indirectly reducing the stimulation of insulin and IGF−1 receptors on cancer cells, which are potent growth factors. [10]

6.3. Management of Polycystic Ovary Syndrome (PCOS)

Metformin is widely used, often off-label, for managing Polycystic Ovary Syndrome (PCOS), a common endocrine disorder characterized by chronic anovulation, hyperandrogenism, and a strong link to insulin resistance.

- **Mechanism in PCOS:** By improving systemic insulin sensitivity, metformin reduces compensatory **hyperinsulinemia**. Since high insulin levels promote androgen production by the ovaries and adrenal glands, lowering insulin helps to restore hormonal balance, reducing hyperandrogenism.
- **Clinical Use:** Metformin is used to improve menstrual cyclicity, hyperandrogenism (acne, hirsutism), and, in some cases, to aid in achieving ovulation and pregnancy. [11]

6.4. Neuro protection and Anti-Aging Potential

The concept of using metformin as a **gero protective agent** (a drug that extends healthspan by preventing age-related diseases) represents an exciting frontier.

- **Anti-Aging Mechanisms:** The AMPK activation pathway is directly linked to processes that combat cellular aging, such as promoting **autophagy** (cellular cleanup) and improving mitochondrial health. Metformin's overall anti-inflammatory and vascular benefits also mitigate age-related decline.
- **The TAME Trial:** The potential is significant enough that the **Targeting Aging with Metformin (TAME) Trial** is a large-scale clinical study designed to test whether metformin can delay the onset of age-related chronic diseases (e.g., cancer, cardiovascular disease, cognitive decline) in a non-diabetic elderly population.
- **Neuroprotection:** While data is mixed, some studies suggest metformin may have neuroprotective effects, possibly reducing the incidence of mild cognitive impairment or Alzheimer's disease by reducing inflammation and promoting beneficial metabolic pathways in the brain.

7. Emerging Research and Future Controversies in Metformin Therapy

Metformin, despite its status as the gold standard, remains at the center of ongoing scientific inquiry and clinical controversy, particularly concerning its mechanism of action and its role in an era defined by newer, cardio protective drugs.

7.1. The Metformin-First Principle Under Scrutiny

The most significant controversy revolves around whether metformin should retain its universal "first-line" status for all patients with T2DM.

- **The CVOT Challenge:** The advent of large-scale Cardiovascular Outcomes Trials (CVOTs) has shown that **SGLT2 inhibitors and GLP−1 receptor agonists (GLP−1RAs)** offer definitive, prospective evidence of reducing major adverse cardiovascular events (MACE), hospitalization for heart failure, and progression of Chronic Kidney Disease (CKD). Metformin's macrovascular benefit, while significant, stems primarily from a subgroup analysis of the UKPDS, not a contemporary CVOT.
- **The Argument for Early Combination or Substitution:** Current guidelines recommend that for patients with established Atherosclerotic Cardiovascular Disease (ASCVD), heart failure, or CKD, an SGLT2i or GLP−1RA should be initiated **early**, often alongside or even *instead* of metformin. This challenges the decades-old paradigm.

- **Defense of Metformin's Primacy:** Advocates argue that metformin's UKPDS-proven mortality reduction, cost-effectiveness, and safety profile make it essential for global population health. For the majority of newly diagnosed patients *without* established ASCVD or CKD, metformin remains the most logical and evidence-backed choice to initiate therapy.

7.2. Definitive Molecular Mechanism Redux

Despite decades of research, the **true, single primary mechanism of action** at therapeutic concentrations remains a subject of debate, with new findings continuously refining the model.

- **Hepatic vs. Gut Action:** Debate continues over whether metformin's *primary* effect is due to AMPK-mediated inhibition of gluconeogenesis in the liver or if the GI-mediated effects (e.g., increased GLP−1 secretion, altered bile acids, mGPD inhibition, or changes to the microbiome) are more critical. New **delayed-release formulations** designed to maximize intestinal exposure and minimize systemic absorption aim to isolate and confirm the contribution of the gut axis.
- **Redox Chemistry:** Recent work on mGPD inhibition and the alteration of the hepatocyte redox state suggests a powerful, AMPK-independent pathway for suppressing gluconeogenesis, shifting the focus from energy sensing to cellular chemistry.

7.3. Pharmacogenomics and Personalized Therapy

Emerging research focuses on utilizing a patient's genetic profile to predict their response to metformin, driving personalization in T2DM treatment.

- **Transporter Gene Polymorphisms:** Variants in the genes encoding the crucial organic cation transporters (OCT1, OCT2, MATEs) have been linked to significant variability in treatment response. For instance, reduced function of the OCT1 transporter in the liver may lead to lower drug efficacy, while variants in MATE transporters may predict a higher likelihood of GI side effects.
- **Clinical Application:** Pharmacogenomics holds the promise of guiding clinicians to select the optimal initial dose or even choose an alternative drug for patients predicted to be non-responders or highly susceptible to adverse effects.

7.4. Expanding Pleiotropic Applications

Ongoing clinical trials are testing metformin in indications far removed from diabetes:

- **Adjuvant Oncology:** Large randomized controlled trials are needed to move the anti-cancer hypothesis beyond observational data. These studies are examining metformin as an adjuvant therapy in specific cancers (e.g., breast, colon) to improve prognosis, leveraging its AMPK-mTOR axis inhibitory effects.
- **Gero protection (TAME Trial):** The **Targeting Aging with Metformin (TAME) Trial** is a groundbreaking effort to determine if metformin can delay the onset of age-related diseases (cardiovascular disease, cancer, dementia) in non-diabetic elderly individuals, solidifying its potential as the first genuine anti-aging drug.

Conclusion

Through a combination of a long history, outstanding clinical trials, and scientific confirmation, Metformin has firmly established itself as the go-to first-line therapeutic agent in the pharmacological treatment of Type 2 Diabetes Mellitus (T2DM). Basic Efficacy: The direct inhibition of Hepatic Glucose Production (HGP) by the OCT1-mediated transport and the subsequent mitochondrial Complex I/AMPK pathway metformin action really goes to the root of the physiopathology of Type 2 Diabetes Mellitus. First of all, the UKPDS created and showed a long-term cardio-protective effect for Metformin in lessening myocardial infarction and all-cause mortality, a "legacy effect" that remains the most compelling rationale for starting the drug as early as possible and continuing its use. Metformin's very good safety profile (no risk of hypoglycemia as monotherapy), weight-neutral effect and low price make it a nearly perfect partner of all other drug classes and thus it is guaranteed to be still there at the maintenance stage of T2DM therapy. Metformin widely known as a T2DM drug. However, its polypharmacology effects, especially the AMPK-mTOR axis activity that could give anti-cancer and geroprotective (aging) effects (TAME Trial), clearly indicates that Metformin's scientific voyage is far from finished. Yes, there are newer agents with cardio-protective effects, which may be the drugs of choice in patients with established cardiovascular or renal disease. However, metformin is still the first line treatment for most patients newly diagnosed with T2DM without these complications thus consolidating its role as the ever-lasting diabetes care cornerstone.

References

[1] H. M. D. H. a. T. C. Mohammed I, "A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan.," 2021.

[2] R. R. e. a. Holman, "10-year follow-up of intensive glucose lowering in type 2 diabetes," *New England Journal of Medicine,* 2008.

[3] A. D. A. (ADA), " Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes," *Diabetes Care,* vol. 1, no. 2024, p. 47, 2024.

[4] R. J. e. a. Shaw, "The AMP-activated protein kinase LKB1 is a tumor suppressor kinase in TSC and targets metformin," *Cancer Cell,* pp. 79-90, 2005.

[5] P. K. e. a. Foreman, "Molecular mechanism of metformin action: A systemic review of cellular targets and signaling pathways," *Molecular Metabolism,* p. 48, 2021.

[6] L. e. a. Gong, "Metformin and SLC22A1 genetic variants on glycemic response and Gastrointestinal symptoms," *Journal of Clinical Endocrinology & Metabolism,* vol. 1, p. 97, 2012.

[7] J. W. e. a. Hunter, " Metformin and the gut microbiome: A systematic review of human studies," *Diabetes Research and Clinical Practice,* p. 173, 2021.

[8] J. e. a. Wong, "Metformin inhibits gluconeogenesis through a redox-dependent mechanism involving mGPD," 2014.

[9] A. e. a. Decensi, "Metformin and cancer risk in patients with type 2 diabetes: A systematic review and meta-analysis. Cancer Prevention Research," pp. 1451-1461, 2010.

[10] R. S. e. a. Legro, "Metformin improves menstrual patterns and decreases androgen levels in women with polycystic ovary syndrome: A randomized, double-blind trial," *Journal of Clinical Endocrinology & Metabolism,* pp. 3377-3386, 2002.

[11] S. E. e. a. Inzucchi, "Metformin in patients with type 2 diabetes and CKD: A systematic review," *JAMA,*

pp. 2668-2675, 2014.

[12] M. e. a. Jahromi, " Vitamin B12 deficiency in patients receiving metformin: A systematic review and meta-analysis," *Journal of Research in Medical Sciences,* p. 44, 2017.

[13] N. e. a. Barzilai, "The TAME (Targeting Aging with Metformin) Trial: Study Design. Aging Cell," 2020.